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By Etest determination of the susceptibilities of 229 Haemophilus influenzae strains isolated in Korea to 10
antibiotics, the isolates were found to be antibiotic nonsusceptible in the following order: ampicillin (58.1%),
trimethoprim-sulfamethoxazole (52%), cefaclor (41.1%), clarithromycin (25.8%), chloramphenicol (14.0%),
amoxicillin-clavulanic acid (13.5%), meropenem (11.7%), cefixime (10.9%), cefuroxime (9.2%), and levofloxacin
(1.3%). The prevalences of each resistance class were 23.6% for -lactamase-negative ampicillin-susceptible
(BLNAS) strains; 37.6% for strains with the TEM-1 type -lactamase gene; 1.3% for strains with the ROB-1
type -lactamase gene; 29.3% for the -lactamase-negative ampicillin-resistant (BLNAR) strains with a
mutation in the ftsI gene, which encodes PBP 3; and 8.3% for -lactamase-positive amoxicillin-clavulanate-
resistant (BLPACR) strains, which showed both resistance mechanisms (i.e., a -lactamase gene and a
mutation in the ftsI gene). The MIC50s of all -lactams, including cephem and meropenem agents, for the
BLNAR strains were two to three times higher than those for the BLNAS strains. This study confirms that the
prevalence of BLNAR and BLPACR strains is relatively high and for the first time confirms the presence of H.
influenzae strains carrying blaROB-1 in Korea. Even though mutations in another gene(s) might be involved in
-lactam resistance, these results suggest that mutations in the ftsI gene are important for the development of
resistance to -lactams in H. influenzae strains in Korea.
Despite the extensive use of antimicrobial therapies and the
availability of the Haemophilus influenzae type b vaccine, H.
influenzae remains a major pathogen in bronchopulmonary
infections as well as ear, nose, and throat infections. Since the
broad use of the H. influenzae type b vaccine in developed
countries, noninvasive, nonencapsulated H. influenzae strains
have been the main source of such respiratory tract infections
(24, 26). H. influenzae can acquire ampicillin resistance
through two different mechanisms. One is the production of
-lactamases, which are referred to as TEM-1 (33) and ROB-1
(16) and which hydrolyze ampicillin enzymatically. Another is
a conformational change in the penicillin-binding proteins
(PBPs), which are enzymes responsible for peptidoglycan syn-
thesis, which results in a reduced affinity to ampicillin (17, 19,
20). Strains with resistance due to the latter mechanism were
isolated in New Zealand for the first time from 1978 to 1980
(20) and were termed -lactamase-negative ampicillin-resis-
tant (BLNAR) H. influenzae strains. Recently, strains showing
both resistance mechanisms were found in clinical isolates, and
such H. influenzae strains have been termed -lactamase pos-
itive ampicillin-clavulanic acid resistant (BLPACR).
From the genetic analysis of the ftsI gene, which encodes
PBP 3 in BLNAR strains, it can be determined that the amino
acid substitution mutations surrounding the highly conserved
KTG (Lys512-Thr-Gly) and SSN (Ser379-Ser-Asn) motifs
would be relevant to -lactam resistance (4, 9, 10, 31). The
substitutions in the ftsI gene have been classified into the fol-
lowing three groups: group I, His is substituted for Arg-517
(Arg517His) near the KTG motif; group II, Lys is substituted
for Asn-526 (Asn526Lys) near the KTG motif; and group III,
three residues (Met-377, Ser-385, and Leu-389) near the SSN
motif are replaced by Ile, Thr, and/or Phe (Met377Ile,
Ser385Thr, and/or Leu389Phe, respectively), in addition to the
replacement of Asn526Lys. Isolates with intermediate ampicil-
lin resistance are commonly found in groups I and II, and
isolates in group III are associated with a higher level of am-
picillin resistance (9, 10, 31). In addition, according to the
genetic characterization of BLNAR isolates in France, group
II BLNAR strains were divided into four subgroups according
to the criteria reported by Dabernat et al. (4). Therefore,
BLNAR strains are classified into six groups: I, IIa, IIb, IIc,
IId, and III. Subgroup IIa includes the strains that have a
substitution at amino acid 526 without a substitution for Ala-
502. Subgroup IIb is defined by a Val-502 substitution for
Ala-502. Subgroup IIc is defined by a Thr-502 substitution
for Ala-502. Subgroup IId is defined by a Val-449 substitution
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for Ile-449. Of the various missense mutations occurring in the
ftsI gene, resistance to -lactams, at least to cephalosporins,
depends largely on the ftsI mutations Arg517His, Asp526Lys,
Ser385Thr, and Leu389Phe (23).
In the United States and Europe, the proportion of BLNAR
isolates remains very low (5, 10, 15), while the proportion of
BLNAR strains in Japan has rapidly increased over the last
decade (9, 21, 23). The high prevalence of these resistant
organisms is attributed to the frequent use of oral and intra-
venous cephem antibiotic agents in Japan (28, 29). These
BLNAR strains show higher levels of resistance to expanded-
and broad-spectrum cephems than non-BLNAR strains, which
can cause serious clinical problems.
This report describes the prevalence and antibiotic suscep-
tibilities of -lactamase-negative ampicillin-susceptible (BLNAS)
and -lactamase-positive ampicillin-resistant (BLPAR) strains;
BLNAR strains in groups I, II, and III; and BLPACR strains
identified by PCR, as well as the substitutions in the ftsI gene
in BLNAR and BLPACR strains.
MATERIALS AND METHODS
Strains. A total of 229 H. influenzae strains, which were collected from out-
patients and hospitalized patients from two tertiary-care hospitals in Seoul,
Korea, from 2000 to 2005, were examined in this study. Of the 229 H. influenzae
strains, 196 strains (85.6%) caused clinical infections, which were treated with
various antibiotics; the rest of the strains (n  33 [14.4%]) did not cause clinical
infections. Testing for the presence of the -lactamase enzyme was performed
with cefinase disks impregnated with nitrocefin (Becton-Dickinson Microbiology
Systems, Cockeysville, MD), as instructed by the manufacturer. The strains H.
influenzae ATCC 49766 (ampicillin susceptible) and H. influenzae ATCC 49247
(BLNAR) were used as controls. The isolates were analyzed by PCR as
described below, and the tested strains were stored at 80°C for subsequent
testing after PCR.
PCR. The PCR cycling conditions were 35 cycles of the following: 94°C for
30 s, 55°C for 30 s, and 72°C for 45 s. PCR was carried out for the H. influenzae
isolates by using the following five sets of primers, which have been reported
previously (9, 10): P6 primers were used to amplify the p6 gene, which encodes
the P6 membrane protein specific for H. influenzae (22). TEM-1 primers were
used to amplify a part of the blaTEM-1 gene, and ROB-1 primers were used to
amplify a part of the blaROB-1 gene (27). PBP3-S primers were used to amplify
a portion of the ftsI gene present in BLNAS strains. The binding positions of the
PBP3-S primers corresponded to the nonsubstituted sequences for the Asn-526
amino acid in the ftsI genes; when Lys was substituted for Asn-526 (Asn-526Lys),
DNA amplification with the PBP3-S primers did not occur. The tested strains
that showed no amplification signal were identified as members of group II (9,
10). PBP3-BLN primers were used to identify group III strains, which contain
Asn526Lys and Ser385Thr amino acid substitutions in the ftsI gene (9, 10).
Serotype b primers were used to amplify a portion of the gene encoding the
serotype b capsule (32). There were no primers that could be used to detect all
isolates suspected of being group I BLNAR strains with the Arg517His substi-
tution, according to the results of disk testing of their susceptibilities. Therefore,
this substitution was detected by subjecting these strains to direct sequencing
(31). On the basis of the PCR results, all H. influenzae strains tested could be
placed in one of four classes: BLNAS strains, which lack all resistance genes;
BLPAR strains, which have the blaTEM-1 or the blaROB-1 gene; BLNAR strains,
which have amino acid substitutions in the ftsI gene; and BLPACR strains, which
have the blaTEM-1 or the blaROB-1 gene and amino acid substitutions in the ftsI
gene.
Antimicrobial susceptibility tests. The antimicrobial susceptibilities were de-
termined by Etest, which is a reliable and appropriate method for the determi-
nation of MICs (13, 25). A broth suspension equivalent to a 0.5 McFarland
standard was inoculated evenly onto Haemophilus test medium agar (Oxoid,
Basingstoke, United Kingdom). After the medium was dry, Etest strips (AB
Biodisk, Solna, Sweden) for 10 antibiotics were placed on the medium, which had
been incubated at 35°C under 5% CO2 for 20 h. H. influenzae ATCC 49766 and
H. influenzae ATCC 49247 were included in each batch as controls. The MICs
were read at the point of the complete inhibition of growth. The following
antibiotics were examined: ampicillin, amoxicillin-clavulanic acid, cefuroxime,
cefaclor, cefixime, meropenem, clarithromycin, levofloxacin, trimethoprim-sulfa-
methoxazole, and chloramphenicol.
Sequencing. For confirmation of a mutation in the ftsI gene, we excluded only
54 strains, which showed positive PCR results with PBP3-S primers and ampi-
cillin-susceptible patterns and which were designated BLNAS. Therefore, we
included 175 H. influenzae strains without reference to -lactamase production in
the ftsI gene sequencing part of the study. The 1.0-kb DNA fragment encoding
the PBP 3 transpeptidase domain was amplified from the chromosomal DNA of
H. influenzae by PCR (31). For confirmation of the presence of blaROB-1, we
sequenced three H. influenzae strains carrying blaROB-1 by PCR. Direct sequenc-
ing was performed with a BigDye Terminator cycle sequencing ready reaction kit
(Applied Biosystems, Foster City, CA) on an ABI Prism 3100 genetic analyzer
(Applied Biosystems).
Statistical analysis. One-way analysis of variance and Tukey’s multiple-com-
parison methods were used to compare the MICs for the BLNAS, BLPAR,
BLNAR, and BLPACR strains. All the analyses were carried out with SPSS
(version 11.5; SPSS Inc., Chicago, IL). A P value of 0.05 was considered
significant.
RESULTS
Antimicrobial susceptibility patterns among H. influenzae
strains by year. Table 1 shows the MIC ranges, the MIC50s,
and the MIC90s of six -lactam agents and four non--lactam
agents for the 229 H. influenzae strains by year of isolation. The
percentages of isolates nonsusceptible to the 10 antibiotics, in
order, were as follows: ampicillin, 58.1%; trimethoprim-sulfa-
methoxazole, 52%; cefaclor, 41.1%; clarithromycin, 25.8%;
chloramphenicol, 14.0%; amoxicillin-clavulanic acid, 13.5%;
meropenem, 11.7%; cefixime, 10.9%; cefuroxime, 9.2%; and
levofloxacin, 1.3%. Although the percentage of ampicillin-re-
sistant isolates appears to have increased each year, this in-
crease was not statistically significant. However, the rates of
resistance to cefixime and chloramphenicol were significantly
higher in 2004 and 2005 (P  0.002 and P  0.008, respec-
tively). Levofloxacin was the most potent agent against H.
influenzae.
The incidence of serotype b among H. influenzae strains. The
incidence of serotype b was 3.1% (7/229 strains). The rates of
isolation of these strains were one strain in 2000, two strains in
2001, two strains in 2002, and two strains in 2003. All had
the resistance genes. Five of the seven isolates (71.4%) were
BLPAR strains carrying blaTEM-1, and two isolates (28.6%)
were group II BLNAR strains. With the exception of one
BLNAR strain, all showed high levels of resistance to ampicil-
lin (MIC ranges, 12 to 256 g/ml). Table 2 shows the clinical
information for the patients from whom the serotype b isolates
were recovered.
Antimicrobial susceptibility patterns among H. influenzae
strains according to whether the strains caused clinical infec-
tions that had been treated. Table 3 shows the MIC ranges,
MIC50s, and the MIC90s of 10 antibiotics for the 196 H. influ-
enzae strains causing clinical infections and the 33 H. influenzae
strains classified as normal flora according to the clinical in-
formation and antibiotic treatment history. The antimicrobial
susceptibility patterns between the two groups were not statis-
tically significantly different.
Susceptibilities among H. influenzae strains according to
resistance gene. The prevalence of each class among the 229 H.
influenzae strains was as follows: 23.6% (n  54) for BLNAS
strains, 37.6% (n 89) for BLPAR strains carrying blaTEM-1 or
blaROB-1, 29.3% (n  67) for BLNAR strains, and 8.3% (n 
19) for BLPACR strains. In particular, group III BLNAR
454 KIM ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 June 1, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://aac.asm
.org/
D
ow
nloaded from
 
strains were not found in Korea, and strains carrying blaROB-1
were found for the first time in Korea. Table 4 shows the MIC
ranges, the MIC50s, and the MIC90s of the 10 antibiotics for
the 229 H. influenzae strains classified into the four groups
according to the PCR results and ftsI sequences. The MIC50s
of the -lactam and cephalosporin agents for the BLNAR
isolates were two to three times greater than those for the
BLNAS isolates. The MIC50s of clarithromycin and chloram-
phenicol for the BLNAR isolates were similar to those for the
BLNAS isolates. The MIC50s of trimethoprim-sulfamethox-
azole were 256 times higher than those for the BLNAS iso-
lates. The MIC50s of ampicillin, cefaclor, cefixime, and tri-
methoprim-sulfamethoxazole for the BLNAR, BLPAR, and
BLPACR isolates were significantly higher than those for the
BLNAS isolates (P  0.000, 0.000, 0.004, and 0.005, respec-
tively).
TABLE 1. Distributions of MICs of 10 antibiotics for 229 H. influenzae strains isolated in Seoul, Korea, by year
Antibiotic(s) Yr of isolation(no. of isolates)
MIC (g/ml) Susceptibility(% of isolates)a P value
50% 90% Range S I R
Ampicillin 2000–2002 (45) 0.75 256 0.016–256 57.8 0.0 42.2 0.342
2003 (69) 6 256 0.125–256 42.0 5.8 52.2
2004 (75) 256 256 0.023–256 36.0 8.0 55.3
2005 (40) 256 256 0.094–256 35.0 5.0 60.0
Total (229) 24 256 0.016–256 41.9 5.2 52.8
Amoxicillin-clavulanic acid 2000–2002 (45) 0.75 2 0.016–8 97.8 0.0 2.2 0.16
2003 (69) 1 8 0.19–256 88.4 0.0 11.6
2004 (75) 1 256 0.016–256 81.3 2.7 16.0
2005 (40) 1 256 0.19–256 80.0 10.0 10.0
Total (229) 1 8 0.016–256 86.5 2.6 10.9
Cefuroxime 2000–2002 (45) 0.5 2 0.016–4 100.0 0.0 0.0 0.11
2003 (69) 0.75 8 0.094–256 89.9 1.4 8.7
2004 (75) 1 256 0.032–256 86.7 1.3 12.0
2005 (40) 1 256 0.094–256 90.0 0.0 10.0
Total (229) 0.75 4 0.016–256 90.8 0.9 8.3
Cefaclor 2000–2002 (45) 2 128 0.05–256 73.3 15.6 11.1 0.066
2003 (69) 4 256 0.094–256 59.4 10.1 30.4
2004 (75) 6 256 0.094–256 60.0 14.7 25.3
2005 (40) 12 256 0.5–256 40.0 25.0 35.0
Total (229) 4 256 0.047–256 59.0 15.3 25.8
Cefixime 2000–2002 (45) 0.047 0.19 0.016–32 97.8 2.2 0.002
2003 (69) 0.047 0.75 0.016–256 92.8 7.2
2004 (75) 0.047 256 0.016–256 78.7 21.3
2005 (40) 0.032 256 0.016–256 97.4 2.6
Total (229) 0.047 24 0.016–256 89.1 10.9
Meropenem 2000–2002 (45) 0.064 0.19 0.01–32 95.6 4.4 0.174
2003 (69) 0.094 32 0.023–32 88.4 11.6
2004 (75) 0.125 32 0.002–32 84.0 16.0
2005 (40) 0.125 32 0.047–32 87.5 12.5
Total (229) 0.094 32 0.002–32 88.3 11.7
Clarithromycin 2000–2002 (45) 12 32 0.016–32 75.6 24.4 0.37
2003 (69) 12 24 0.016–256 79.7 15.9 4.3
2004 (75) 16 24 0.48–256 70.7 24.0 5.3
2005 (40) 12 32 1.00–256 74.2 21.8 3.9
Total (229) 12 32 0.016–256 74.2 21.8 3.9
Levofloxacin 2000–2002 (45) 0.016 1 0.004–1.5 100.0 0.0 0.154
2003 (69) 0.016 0.047 0.008–32 95.7 4.3
2004 (75) 0.023 0.032 0.004–2 100.0 0.0
2005 (40) 0.016 0.0455 0.002–0.19 100.0 0.0
Total (229) 0.016 0.047 0.002–32 98.7 1.3
Trimethoprim-sulfamethoxazole 2000–2002 (45) 0.75 32 0.032–32 48.9 4.4 46.7 0.802
2003 (69) 0.38 32 0.016–32 50.7 2.9 46.4
2004 (75) 32 32 0.02–32 46.3 0.0 54.7
2005 (40) 32 32 0.032–32 48.0 1.7 50.2
Total (229) 4 32 0.016–32 48.0 1.7 50.2
Chloramphenicol 2000–2002 (45) 0.75 16 0.075–48 84.4 15.6 0.008
2003 (69) 0.5 6 0.19–16 85.5 7.2 7.2
2004 (75) 0.5 4 0.064–12 89.3 4.0 6.7
2005 (40) 0.5 8 0.016–16 82.5 2.5 15.0
Total (229) 0.5 6 0.064–48 86.0 3.9 10.0
a S, susceptible; I, intermediate; R, resistant.
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Sequencing of ftsI gene. Table 5 shows the deduced amino
acid substitutions in parts of the ftsI gene around the KTG
motif and the SSN motif in the BLNAR (n  67) and
BLPACR (n  19) strains. In this part of the ftsI gene, various
mutations were identified, and 14 different mutation patterns
were detected in 86 clinical strains. The mutation patterns
were classified into two groups according to the different
amino acid substitutions without reference to -lactamase pro-
duction. In groups I (n  4) and II (n  81), His-517 was
substituted for Arg-517 and Lys-526 was substituted for Asn-
526, respectively. In one isolate, these substitutions (at amino
acids 517 and 526) were observed simultaneously in the same
strain. None of the clinical isolates from Korea belonged to the
group III proposed by Ubukata and colleagues (10, 31). Group
II was divided into four subgroups according to the criteria
reported by Dabernat et al. (4). Isolates in subgroup IIa (n 
44), subgroup IIb (n  24), and subgroup IIc (n  13) but not
subgroup IId (n  0) were identified. BLPACR strains, which
do carry blaTEM-1 (n  19), were found in all subgroups iden-
tified for the BLNAR strains (subgroup I, n  3; subgroup IIa,
n  10; subgroup IIb, n  3; subgroup IIc, n  2; and sub-
groups I and IIb, n  1).
Changes in resistance patterns among H. influenzae strains
by year. Table 6 shows the annual changes in the incidence of
resistant strains between 2000 and 2005. Among those cases,
the prevalence of the BLNAS strains decreased markedly from
2000 to 2002: 33.3% (n  15) in 2000 to 2002, 24.6% (n  17)
in 2003, 21.3% (n  16) in 2004, and 11.1% (n  6) in 2005.
Although the incidence of BLNAR groups I and II was rela-
tively high each year, no strain of BLNAR group III was found.
TABLE 2. Clinical information for patients from whom serotype b H. influenzae strains were recovered
Characteristic SMC0001 SMC0105 SMC0120 SMC0203 SMC0208 SMC0304 SMC0340
Yr of isolation 2000 2001 2001 2002 2002 2003 2003
Gendera M M M F F F F
Age (yr) 7 59 5 83 38 7 12
Diagnosis Paransal sinusitis Community-acquired
pneumonia
Paransal sinusitis Sepsis Bronchi-ectasis Chronic sinusitis Paransal sinusitis
Specimen Nasopharyngeal Sputum Nasopharyngeal Blood Sputum Nasopharyngeal Nasopharyngeal
Resistance type BLPAR BLPAR BLPAR BLPAR BLNAR BLNAR BLPAR
Treatment Clarithromycin Levofloxacin,
ceftriaxone
Amoxicillin-
clavulanic acid
Ceftriaxone,
metronidazole,
gentamicin
None Cefuroxime Amoxicillin-
clavulanic acid
a M, male; F, female.
TABLE 3. Distributions of MICs of 10 antibiotics for H. influenzae strains according to whether the strains caused clinical infections that had
been treated or were normal flora (no treatment)
Antibiotic(s) Treatment(no. of isolates)
MIC (g/ml)
P value
50% 90% Range
Ampicillin No treatment (33) 0.38 256 0.016–256 0.088
Treatment (196) 24 256 0.023–256
Amoxicillin-clavulanic acid No treatment (33) 0.75 256 0.016–256 0.968
Treatment (196) 1 8 0.016–256
Cefuroxime No treatment (33) 0.5 256 0.016–256 0.976
Treatment (196) 1 8 0.016–256
Cefaclor No treatment (33) 2 256 0.094–256 0.452
Treatment (196) 8 256 0.047–256
Cefixime No treatment (33) 0.047 32 0.023–256 0.999
Treatment (196) 0.047 0.75 0.016–256
Meropenem No treatment (33) 0.094 32 0.016–32 0.227
Treatment (196) 0.094 32 0.002–32
Clarithromycin No treatment (33) 16 32 0.016–32 0.284
Treatment (196) 16 32 0.016–256
Levofloxacin No treatment (33) 0.023 1 0.016–6 0.800
Treatment (196) 0.016 0.32 0.002–32
Trimethoprim-sulfamethoxazole No treatment (33) 32 32 0.016–32 0.719
Treatment (196) 4 32 0.016–32
Chloramphenicol No treatment (33) 0.75 4 0.19–8 0.057
Treatment (196) 0.5 8 0.06–48
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A BLPACR strain was first identified in 2003. The incidence of
BLPAR strains varied every year.
DISCUSSION
The in vitro activities and rates of resistance to the 10 anti-
microbial agents obtained in the present study showed that
ampicillin, trimethoprim-sulfamethoxazole, and cefaclor were
problematic in terms of resistance, with overall rates of resis-
tance to these agents of 52.8%, 50.2% and 25.8%, respectively.
Except for levofloxacin, the rates of resistance to the other
antimicrobial agents were relatively high, with rates ranging
from 3.9 to 11.8%. Three isolates (1.3%) had levofloxacin
MICs of 2 g/ml. During the 1990s there has been a shift
away from the use of amoxicillin and less potent oral cepha-
losporins, such as cefaclor, loracarbef, and cefprozil, for the
treatment of H. influenzae infections toward the use of amoxi-
cillin-clavulanate, macrolides, more potent advanced oral
cephalosporins, and fluoroquinolones. The quinolones are ex-
pected to become increasingly important empirical treatment
options if the trends toward increasing rates of resistance
among H. influenzae pathogens continues, particularly among
the oral agents commonly prescribed (2, 12). Data from the
SENTRY program, which analyzed H. influenzae isolates with
TABLE 4. Distributions of MICs of 10 antibiotics for H. influenzae strains by resistance gene, as identified by PCR and direct sequencing
Antibiotic(s) Resistance type(no. of isolates)
MIC (g/ml) Susceptibility (% of isolates)a
P value
50% 90% Range S I R
Ampicillin BLNAS (54) 0.25 0.38 0.016–256 100.0 0.0 0.0 0.000
BLPAR (89) 256 256 0.19–256 0.0 2.2 97.8
BLNAR (67) 0.75 256 0.016–256 62.7 14.9 22.4
BLPACR (19) 256 256 32–256 0.0 0.0 100.0
Amoxicillin-clavulanic acid BLNAS (54) 0.5 1 0.016–256 100.0 0.0 0.0 0.054
BLPAR (89) 1.5 12 0.25–256 80.9 3.4 15.7
BLNAR (67) 1 256 0.016–256 86.6 3.0 10.4
BLPACR (19) 1.5 256 0.38–256 73.7 5.3 21.0
Cefuroxime BLNAS (54) 0.5 1 0.016–256 98.1 0.0 1.9 0.104
BLPAR (89) 1 256 0.13–256 88.8 0.0 11.2
BLNAR (67) 1 8 0.016–256 89.6 3.0 7.5
BLPACR (19) 1 256 0.38–256 84.2 0.0 15.8
Cefaclor BLNAS (54) 2 6 0.05–256 90.7 5.6 3.7 0.000
BLPAR (89) 12 256 0.13–256 43.8 13.5 42.7
BLNAR (67) 6 256 0.05–256 58.2 22.4 19.4
BLPACR (19) 16 256 1–256 42.1 26.3 31.6
Cefixime BLNAS (54) 0.023 0.064 0.004–256 98.1 1.9 0.004
BLPAR (89) 0.047 32 0.016–256 92.0 8.0
BLNAR (67) 0.064 32 0.016–256 85.1 14.9
BLPACR (19) 0.064 256 0.05–256 73.7 26.3
Meropenem BLNAS (54) 0.064 0.125 0.004–32 94.4 5.6 0.135
BLPAR (89) 0.094 32 0.023–32 83.1 16.9
BLNAR (67) 0.125 32 0.01–32 88.1 11.9
BLPACR (19) 0.19 0.38 0.09–32 94.7 5.3
Clarithromycin BLNAS (54) 16 24 0.016–96 83.3 13.0 3.7 0.092
BLPAR (89) 16 32 0.038–256 66.3 32.6 1.1
BLNAR (67) 12 24 0.016–256 79.1 14.9 6.0
BLPACR (19) 16 256 8–32 68.4 21.1 10.5
Levofloxacin BLNAS (54) 0.016 0.032 0.004–32 98.1 1.9 0.146
BLPAR (89) 0.016 0.032 0.008–0.25 100.0 0.0
BLNAR (67) 0.023 1 0.004–32 98.5 1.5
BLPACR (19) 0.016 0.047 0.016–0.03 94.7 5.3
Trimethoprim-sulfamethoxazole BLNAS (54) 0.125 32 0.016–32 63.0 3.7 33.3 0.005
BLPAR (89) 32 32 0.016–32 42.7 1.1 56.2
BLNAR (67) 32 32 0.032–32 47.8 1.5 50.7
BLPACR (19) 32 32 0.09–32 31.6 0.0 68.4
Chloramphenicol BLNAS (54) 0.5 0.75 0.064–48 96.3 0.0 3.7 0.541
BLPAR (89) 0.75 12 0.13–48 78.7 5.6 15.7
BLNAR (67) 0.5 6 0.016–48 88.1 6.0 6.0
BLPACR (19) 0.5 8 0.5–8.0 84.2 0.0 15.8
a S, susceptible; I, intermediate; R, resistant.
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reduced susceptibilities to fluoroquinolones, determined that
the rate of resistance remained very low (0.15%) between 1997
and 2001 in North America, Latin America, and Europe (2).
Although the SENTRY study did not evaluate isolates from
Asia or the Western Pacific, based on the findings of this study,
the prevalence of quinolone-resistant H. influenzae strains in
Korea was relatively higher from 2000 to 2005. gyrA and parC
mutations, which are located in the H. influenzae quinolone
resistance-determining region that leads to resistance or re-
duced susceptibility to ciprofloxacin, have been reported (2, 3,
8). Fluoroquinolones, particularly the newer class of com-
pounds with increased potencies for the treatment of H. influ-
enzae infections, are an excellent alternative to other orally
administered compounds, such as -lactams (cephalosporins
and penicillins) and macrolides (erythromycin, azithromycin,
and clarithromycin). The very low rates of levofloxacin-resis-
tant H. influenzae isolates with reduced susceptibilities docu-
mented in this study suggest that this drug class will soon be an
effective contemporary treatment for H. influenzae infections,
provided that it is used prudently.
Serotype b strains were not discovered in Korea until after
2003 in this study, and the total incidence was 3.1% (7/229).
The introduction of the H. influenzae type b vaccine might have
contributed to the decreased incidence of H. influenzae type b
infections after 2003.
The detection of BLNAR strains with decreased suscepti-
bilities to -lactam antibiotics is controversial. No universal
single resistance breakpoint has been chosen, and different
values have been proposed (1, 11). Barry et al. (1) stressed the
difficulty in standardizing procedures and reaching a universal
definition of a BLNAR strain. The clinical relevance of resis-
tance through the modification of PBPs has yet to be demon-
strated unambiguously. The role of such resistant strains in
therapeutic failure has not been clearly demonstrated, and
there are few cases of therapeutic failure when resistant strains
are present (18). Understanding of the intricacies of the resis-
tance mechanisms and the use of strains that have been inves-
tigated genetically should lead to the development of reliable
tests for the detection of such strains.
A large number of silent mutations occur in the DNA en-
coding the transpeptidase domain of PBP 3, with the DNA
sequences of different strains diverging as much as 7%. The
different patterns of amino acid substitution obtained with the
strains studied can be attributed to groups I and II proposed by
Ubukata et al. (31). The situation is quite different for the
Korean strains. The absence of strains belonging to group III
has been proven among isolates from France (4, 6), Austria
(6), Germany (6), Italy (6), Holland (6), Poland (6), Portugal
(6), Spain (6), the United Kingdom (6), and Turkey (6). A
triple substitution at positions 377, 385, and 389, located near
TABLE 5. Amino acid substitutions around KTG motif and SSN motif of ftsI genes of BLNAR and BLPACR H. influenzae strainsa
Group No. ofisolates
Amino acid substitution
377 Met 385 Ser 389 Leu 386 Arg 398 Glu 437 Ala 448 Ile 454 Ala 465 Thr 490 Gly 495 Ile 502 Ala 517 Arg 526 Asn
I 3 Ala His Asn
I 1 Val His Asn
IIab 32 Ala Lys
IIa 4 Val Ala Lys
IIa 2 Gly Ala Lys
IIa 2 Val Ala Lys
IIa 1 Asp Ser Met Ala Lys
IIa 1 Ser Ala Lys
IIa 1 Ala Ala Lys
IIa 1 Glu Ala Lys
IIbb 17 Val Lys
IIb 7 Ile Val Lys
IIcb 13 Thr Lys
I  IIb 1 Ile Val His Lys
a A total of 67 BLNAR H. influenzae strains and 19 BLPACR H. influenzae strains were tested.
b Strains that had ftsI gene mutations were classified into six groups: groups I, IIa, IIb, IIc, IId, and III. Group II was divided into four subgroups according to the
criteria reported by Dabernat et al. (4). Subgroup IIa includes strains that have a substitution at amino acid 526 without a substitution for Ala-502. Subgroup IIb is
defined by a Val-502 substitution for Ala-502. Subgroup IIc is defined by a Thr-502 substitution for Ala-502. Subgroup IId is defined by a Val-449 substitution for
Ile-449. Subgroup IId was not found in this study.
TABLE 6. Changes in resistance patterns among H. influenzae strains from clinical isolates, by year, as identified by PCR and direct sequencing
Resistance class
No. (%) of strains in the following yr:
2000–2002 2003 2004 2005 Total
BLNAS 15 (33.3) 17 (24.6) 16 (21.3) 6 (11.1) 54 (23.6)
BLPAR, blaTEM-1 19 (42.2) 21 (30.4) 26 (34.7) 20 (50) 86 (37.6)
BLPAR, blaROB-1 0 (0) 0 (0) 2 (2.7) 1 (2.5) 3 (1.3)
BLNAR (groups I and II) 11 (24.4) 23 (33.3) 23 (30.7) 10 (25) 67 (29.3)
BLNAR (group III) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
BLPACR 0 (0) 8 (11.6) 8 (10.7) 3 (7.5) 19 (8.3)
Total 45 (19.7) 69 (30.1) 75 (32.8) 40 (17.5) 229 (100)
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the conserved SSN motif, has not been found in Korean or
European strains. The Japanese strains classified into group III
were resistant to cephem antibiotics: the cefotaxime MICs for
these strains were 128 to 256 times higher than those for the
susceptible strains. Although none of the Korean strains were
found to belong to group III, some strains showed high levels
of resistance to cephems. The inappropriate use of oral anti-
biotics for the treatment of community-acquired bronchopul-
monary and ear, nose, and throat infections appears to be
responsible for the selection of BLNAR strains. This difference
might be related to the dissimilar antibiotic prescription habits
in different countries.
Previous studies with group I and group II BLNAR strains
of H. influenzae from Japan, France, and North America indi-
cate that mutations in ftsI, which encodes PBP 3, confer am-
picillin MICs of 1 to 4 g/ml (4, 6, 30, 31). Several BLNAR
strains with ampicillin MICs of 4 to 16 g/ml were recently
isolated from North America and were studied (14). The geo-
metric mean ampicillin MICs for several clinical isolates
ranged from 8 to 10.56 g/ml. An analysis of the resistant
BLNAR strains revealed frameshift insertions in acrR for all
the high-level-ampicillin-resistant isolates. acrR was intact in
all the low-level-ampicillin-resistant and ampicillin-susceptible
strains tested. That report showed that the BLNAR strains
with high ampicillin MICs have combined resistance mecha-
nisms as a result of changes in the genes for PBP 3 and in the
AcrAB efflux pump (14). Kaczmarek et al. (14) suggested that
BLNAR strains of H. influenzae with mutations in the AcrAB
repressor gene acrR can occur clinically and that such dual-
target mutants can have higher ampicillin MICs (in the 8- to
16-g/ml range). In this study, 20.9% (14/67) of the BLNAR
strains showed higher levels of ampicillin resistance (MICs,8
g/ml). Now that the resistance mechanisms of the BLNAR
strains are being established, all possible measures should be
taken to prevent their selection. In addition, the involvement
of other resistance mechanisms in current or future strains
should be considered.
Different studies carried out with BLNAR strains have
shown their genotypic and phenotypic heterogeneities and the
absence of the clonal propagation of these strains (6, 7, 10, 19).
On the basis of multilocus sequence typing, which was carried
out for some BLNAR and BLPACR strains (data not shown),
an analysis of the clonality of these strains in this study showed
that they had heterogeneous sequence types.
In summary, the emergence of the BLNAR phenotype of H.
influenzae was demonstrated, with the prevalence ranging from
24.4% to 33.3%. These BLNAR strains are more resistant to
cephems than the BLNAS strains. It is important for labora-
tory technicians to use strategies that not only allow the routine
examination of H. influenzae strains for the production of
-lactamase but also allow for determination of the presence
of the resistance gene by using the PCR techniques described
in this report. Even though mutations in another gene(s) might
be involved in -lactam resistance, these results suggest that
mutations in the ftsI gene are important for the development of
resistance to -lactams in H. influenzae strains in Korea. In
addition, the patterns of susceptibility to cefixime, cefuroxime,
meropenem, and levofloxacin, to which ampicillin-resistant H.
influenzae strains are traditionally believed to be susceptible,
show the presence of resistant strains. Therefore, continued
monitoring of the susceptibility trends will be needed to guide
the appropriate antimicrobial chemotherapy.
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